| CPC G16H 10/20 (2018.01) [A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61P 11/06 (2018.01); G06F 16/9035 (2019.01); G06F 16/9038 (2019.01); G06Q 30/0637 (2013.01); G16H 70/40 (2018.01)] | 26 Claims |
|
1. A method of treating or preventing symptoms of asthma in a human subject with an over-the-counter corticosteroid pharmaceutical composition, the method comprising:
A) providing a first survey for obtaining a first plurality of survey results about the subject, via a first computer system having a processor programed to perform the first survey, wherein the first plurality of survey results indicates:
whether the subject is taking another steroid medication,
an age of the subject,
a pulmonary function status of the subject,
a severity of the subject's asthma,
whether the subject has an untreated infection,
a surgery status of the subject,
a bone density status of the subject, and
whether the subject has ever had cataracts or glaucoma;
B) applying an algorithm to the first plurality of survey results, via a second computer system having a process programed to perform the algorithm, wherein the algorithm is associated with an over-the-counter dosage of the corticosteroid pharmaceutical composition that is lower than a prescription dosage, and wherein the algorithm:
i) runs all or a portion of the first plurality of survey results against a first plurality of filters of a first category class, wherein, when a respective filter in the first plurality of filters is fired, the subject is deemed not qualified for provision of the corticosteroid pharmaceutical composition and the method is terminated without authorizing provision of the corticosteroid pharmaceutical composition to the subject, wherein the first plurality of filters comprises:
a first steroid medication filter that is fired at least when the first plurality of survey results indicates that the subject is taking a steroid medication,
an age filter,
a first pulmonary function filter that is fired at least when the first plurality of survey results indicates that the subject has compromised pulmonary function, and
an asthma severity filter;
ii) runs all or a portion of the first plurality of survey results against a second plurality of filters of a second category class, wherein, when a respective filter in the second plurality of filters is fired, the subject is provided with a warning corresponding to the respective filter, and wherein the second plurality of filters comprises:
a first infection filter that is fired at least when the first plurality of survey results indicates that the subject has a severe, untreated infection,
a first surgery filter that is fired at least when the first plurality of survey results indicates that the subject is planning on undergoing surgery,
a first bone density filter that is fired at least when the first plurality of survey results indicates that the subject has decreased bone mineral density, and
a first ocular disease filter that is fired at least when the first plurality of survey results indicates that the subject has ever had cataracts or glaucoma;
iii) obtains acknowledgment from the subject for the warning issued to the subject by any filter in the second plurality of filters; and
iv) proceeds with a fulfillment process when a) no filter in the first plurality of filters has been fired and b) the subject has acknowledged each warning associated with each filter in the second plurality of filters that was fired, wherein the fulfillment process comprises:
storing, in a memory of the second computer system, an indication in a subject profile of an initial order for the corticosteroid pharmaceutical composition,
communicating an over-the-counter drug facts label for the corticosteroid pharmaceutical composition to the subject, and
authorizing, upon confirmation from the subject that the over-the-counter drug facts label has been received and read, provision of the corticosteroid pharmaceutical composition to the subject; and
C) administering the corticosteroid pharmaceutical composition to the subject at the over-the-counter dosage that is lower than a prescription dosage after authorization of the provision.
|